The success rate for central nervous system (CNS) drug candidates in the clinic is relatively low compared to the industry average across other therapeutic areas. Penetration through the blood-brain barrier (BBB) to reach the therapeutic target is a major obstacle in development. The rapid CNS penetration of salvinorin A has suggested that the neoderodane nucleus offers an excellent scaffold for developing antiproliferative compounds that enter the CNS. The Liebeskind-Srogl reaction was used as the main carbon-carbon bond-forming step toward the synthesis of quinone-containing salvinorin A analogues. Quinone-containing salvinorin A analogues were shown to have antiproliferative activity against the MCF7 breast cancer cell line, but show no significant activity at the x-opioid receptors. In an in vitro model of BBB penetration, quinone-containing salvinorin A analogues were shown to passively diffuse across the cell monolayer. The analogues, however, are substrates of P-glycoprotein, and thus further modification of the molecules is needed to reduce the affinity for the efflux transporter
Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A
Vasiljevik, T., Groer, CE., Lehner, K., Navarro, H., & Prisinzano, TE. (2014). Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A. Journal of Natural Products, 77(8), 1817-1824. https://doi.org/10.1021/np5002048
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Recent Publications
OCCASIONAL PAPER
OCCASIONAL PAPER
Culturally informed community engagement
Article
Far-right and Jihadi terrorism within the United States
Article